• 1
    Ayoola EA, Balayan MS, Deinhardt F, Gust I, Kureshi AW, Maynard JE, Nayak NC, et al. Progress in the control of viral hepatitis: memorandum from a WHO meeting. Bull World Health Org 1988; 66: 443455.
  • 2
    Lok A. Treatment of chronic hepatitis B. J Viral Hepat 1994; 1: 105124.
  • 3
    Sherker A, Marion, P. Hepadnaviruses and hepatocellular carcinoma. Annu Rev Microbiol 1991; 45: 475508.
  • 4
    Locarnini SA, Civitico GM, Newbold JE. Hepatitis B: new approaches for antiviral chemotherapy. Antiviral Chem Chemother 1996; 7: 5364.
  • 5
    Shaw T, Locarnini, S. Hepatic purine and pyrimidine metabolism. Implications for chemotherapy in viral hepatitis. Liver 1995; 15: 169184.
  • 6
    Sommadossi J.-P. Treatment of hepatitis B by nucleoside analogs: still a reality. Curr Opin Infect Dis 1994; 7: 678682.
  • 7
    Summers J, Mason WS. Replication of the genome of a hepatitis B–like virus by reverse transcription of an RNA intermediate. Cell 1982; 29: 403415.
  • 8
    Wang G-H, Seeger C. The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis. Cell 1992; 71: 663670.
  • 9
    Zoulim F, Dannaoui E, Trepo C. Inhibitory effect of penciclovir on the priming of hepadnavirus reverse transcription. Abstracts of the 35th Interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society Microbiology, 1995: 182.
  • 10
    Davis MG, Wilson JE, VanDraanen NA, Miller WH, Freeman GA, Daluge SM, Boyd FL, et al. DNA polymerase activity of hepatitis B virus particles: differential inhibition by L-enantiomers of nucleotide analogs. Antiviral Res 1996; 30: 133145.
  • 11
    Benhamou Y, Dohin E, Lunel-Fabiani F, Poynard T, Huraux JM, Katlama C, Opolon P, et al. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet 1995; 345: 397397.
  • 12
    Pluda JM, Cooley TP, Montaner JS, Shay LE, Reinhalter NE, Warthan SN, Ruedy J, et al. A phase I/II study of 2′-deoxy-3′- thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J Infect Dis 1995; 171: 14381447.
  • 13
    Chang CN, Skalski Y, Zhou JH, Cheng Y.-C. Biochemical pharmacology of (+) and (-) 2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. J Biol Chem 1992; 267: 2241422420.
  • 14
    Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin MA. Preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 16571661.
  • 15
    Doong S-L, Tsai C-H, Schinazi RF, Liotta DC, Cheng Y.-C. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991; 88: 84958499.
  • 16
    Severini A, Liu X-Y, Wilson JS, Tyrrell DLJ. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-β-1–2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1995; 39: 14301435.
  • 17
    Tyrell DLJ, Fischer K, Cameron J. 2′,3′ Dideoxy 3′ thiacytidine (lamivudine) treatment of chimpanzees chronically infected with hepatitis B virus (HBV) results in rapid suppression of HBV DNA in sera. In: Program and Abstracts of the 18th International Symposium on Viral Hepatitis and Liver Disease. Viral Hepatitis Foundation of Japan. Tokyo, 1993: 156.
  • 18
    Condreay LD, Condreay JP, Jansen RW, Pfaff MT, Averett DR. (-)cis-5-fluoro-1- [2-(hydroxymethyl)-1,3-oxathiolan-5-y1]cytosine (524W91) inhibits hepatitis B virus replication in primary human hepatocytes. Antimicrob Agents Chemother 1996; 40: 520523.
  • 19
    Soudeyns H, Yao X-J, Gao Q, Belleau B, Kraus J-L, Nguyen-Ba N, Spira B, et al. Anti-immunodeficiency virus type I activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother 1991; 35: 13861390.
  • 20
    Hart GJ, Orr DC, Penn CR, Figueiredo HT, Gray NM, Boehme RE, Cameron JM. Effects of (-)-2′-deoxy-3′-thiacytidine (3TC) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. Antimicrob Agents Chemother 1992; 36: 16881694.
  • 21
    Civitico G, Wan YY, Luscombe C, Bishop N, Tachedjian G, Gust I, Locarnini, S. Antiviral strategies in hepatitis B virus infection. II. Inhibition of duck hepatitis B virus in vitro using conventional antiviral agents and supercoiled-DNA active compounds. J Med Virol 1990; 31: 9097.
  • 22
    Civitico G, Shaw T, Locarnini S. Interaction between ganciclovir and foscarnet as inhibitors of duck hepatitis B virus replication in vitro. Antimicrobial Agents Chemother 1996; 40: 11801185.
  • 23
    Dean J, Bowden S, Locarnini S. Reversion of duck hepatitis B virus DNA replication in vivo following cessation of treatment with the nucleoside analogue ganciclovir. Antiviral Res 1995; 27: 171178.
  • 24
    Luscombe C, Pedersen J, Bowden S, Locarnini S. Alterations in intrahepatic expression of duck hepatitis B viral markers with ganciclovir therapy. Liver 1994; 14: 182192.
  • 25
    Luscombe C, Pedersen J, Uren E, Locarnini S. Long-term ganciclovir chemotherapy for congenital duck hepatitis B virus infection in vivo: effect on intrahepatic viral DNA, RNA, and protein expression. Hepatology 1996; 24: 776773.
  • 26
    McMillan JS, Shaw T, Angus PW, Locarnini S. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology 1995; 22: 3643.
  • 27
    Shaw T, Amor P, Civitico G, Boyd M, Locarnini S. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob Agents Chemother 1994; 38: 719723.
  • 28
    Korba BE. In vitro evaluation of combination therapies against hepatitis B virus replication. Antiviral Res 1995; 29: 4951.
  • 29
    Korba BE, Boyd MR. Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Antimicrob Agents Chemother 1996; 40: 12821284.
  • 30
    Lin E, Luscombe C, Wang YY, Shaw T, Locarnini S. The guanine nucleoside analogue penciclovir is active against chronic duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother 1996; 40: 413418.
  • 31
    Shaw T, Mok SS, Locarnini SA. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhinition of HBV replication by penciclovir. Hepatology 1996; 24: 9961002.
  • 32
    Martin JL, Brown CE, Matthews-Davis N, Reardon JE. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother 1994; 38: 27432749.
  • 33
    Ilsley DD, Lee S-H, Miller WH, Kuchta RD. Acyclic guanosine analogs inhibit DNA polymerases a, d and e with very different potencies and have unique mechanisms of action. Biochemistry 1995; 34: 25042510.
  • 34
    Fautz R, Husein B, Hechenberger C. Application of the neutral red assay (NR assay) to monolayer cultures of primary hepatocytes: rapid colorimetric viability determination for the unscheduled DNA synthesis test (UDS). Mutation Res 1991; 253: 173179.
  • 35
    Nakabayashi, H, Taketa K, Miyano K, Yamane K, Soto J. Growth of human hepatoma cell lines with differentiated functions in chemically defined media. Cancer Res 1982; 42: 38583862.
  • 36
    Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995; 47: 331385.
  • 37
    Belen'kii MS, Schinazi RF. Multiple drug effect analysis with confidence interval. Antiviral Res 1994; 25: 111.
  • 38
    Berenbaum MC. What is synergy? Pharmacol Rev 1989; 41: 93141.
  • 39
    Martinez-Irujo JJ, Villahermosa ML, Alberdi E, Santiago E. A chequerboard method to evaluate interactions between drugs. Biochem Pharmacol 1996; 51: 635644.
  • 40
    de Jong MD, Boucher CAB, Galasso GJ, Hirsch MS, Kern ER, Lange JMA, Richman DD. Consensus symposium on combined antiviral therapy. Antiviral Res 1995; 29: 529.
  • 41
    Civitico G, Locarnini, S. The half-life of duck hepatitis B virus supercoiled DNA in congenitally infected primary hepatocyte cultures. Virology 1994; 203: 8189.
  • 42
    Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996; 93: 43984402.
  • 43
    Ling R, Mutimer D, Ahmed M, Boxall EH, Ellas E, Dusheiko GM, Harrison TJ. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24: 711713.
  • 44
    Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J, Angus P, et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 26: in press.
  • 45
    Boucher CAB, Cammack N, Schipper P, Schuurman R, Rouse P, Wainberg MA, Cameron JM. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human Immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1993; 37: 22312234.
  • 46
    Fischer KP, Tyrrell DLJ. Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(-)-β-1-2′,3′-dideoxy-3′-thiacytidine] in vitro. Antimicrob Agents Chemother 1996; 40: 19571960.
  • 47
    Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DLJ. Mutation in HBV RNA–dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 714717.
  • 48
    Main J, Brown JL, Howells C, Galassini R, Karayiannis P, Georgiou P, Atkinson G, et al. A double-blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J Viral Hepat 1996; 3: 211215.
  • 49
    Boike SC, Pue M, Audet PR, Freed MI, Fairless A, Ilson BE, Zariffa N, et al. Pharmacokinetics of famciclovir in subjects with chronic hepatic disease. J Clin Pharmacol 1994; 34: 11991207.
  • 50
    White EL, Parker WB, Ross LJ, Shannon WM. Lack of synergy in the inhibition of HIV-1 reverse transcriptase by combinations of the 5′-triphosphates of various anti-HIV nucleoside analogs. Antiviral Res 1994; 22: 295308.
  • 51
    Xie, H, Voronkov M, Liotta DC, Korba BA, Schinazi RF, Richman DD, Hostetler KY. Phosphatidyl-2′,3′-dideoxy-3′-thiacytidine: synthesis and antiviral activity in hepatitis B- and HIV-1-infected cells. Antiviral Res 1995; 28: 113120.
  • 52
    Shewach DS, Liotta DC, Schinazi RF. Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2′-deoxycytidine kinase. Biochem Pharmacol 1993; 45: 15401543.
  • 53
    Singhal RL, Abonyi M, Weber G. Nutritional and hormonal regulation of liver deoxycytidine kinase activity. Biochem Biophys Res Commun 1993; 194: 4549.
  • 54
    Arner E, Eriksson S. Mammalian deoxyribonucleoside kinases. Pharmacol Ther 1995; 67: 155186.
  • 55
    Bianchi V, Borella S, Caderazzo F, Ferraro P, Chieco-Bianchi L, Reichard P. Inhibition of ribonucleotide reductase by 2′-substituted deoxycytidine analogs: possible application in AIDS treatment. Proc Natl Acad Sci U S A 1994; 91: 84038407.
  • 56
    Heringa J, Argos P. Evolution of viruses as recorded by their polymerase sequences. In: MorseSS, ed. The Evolutionary Biology of Viruses. New York: Raven, 1994: 87103.
  • 57
    Girones R, Miller RH. Mutation rates of hepadnavirus genomes. Virology 1989; 170: 595597.